US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
ES2283012T3
(es)
|
1996-01-04 |
2007-10-16 |
Novartis Vaccines And Diagnostics, Inc. |
Bacterioferritina de helicobacter pylori.
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
SI1077722T1
(sl)
|
1998-05-22 |
2007-02-28 |
Ottawa Health Research Inst |
Metode in produkti za induciranje sluznicne imunosti
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
ATE376825T1
(de)
*
|
1999-09-24 |
2007-11-15 |
Glaxosmithkline Biolog Sa |
Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
|
TR200200777T2
(tr)
*
|
1999-09-24 |
2002-09-23 |
Smithkline Beecham Biologicals S.A. |
Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
|
US20010044416A1
(en)
*
|
2000-01-20 |
2001-11-22 |
Mccluskie Michael J. |
Immunostimulatory nucleic acids for inducing a Th2 immune response
|
CA2400842C
(en)
|
2000-02-23 |
2013-01-15 |
Smithkline Beecham Biologicals S.A. |
Novel compounds
|
ES2305086T3
(es)
|
2000-05-19 |
2008-11-01 |
Corixa Corporation |
Tratamiento profilactico y terapeutico de enfermedades alergicas, autoinmunes e infecciosas con compuestos con base de monosacaridos.
|
DK2133100T3
(da)
|
2000-06-20 |
2012-01-23 |
Corixa Corp |
MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf
|
ATE396265T1
(de)
|
2000-06-28 |
2008-06-15 |
Corixa Corp |
Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
|
KR20030055275A
(ko)
*
|
2000-10-02 |
2003-07-02 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
분할 외피 바이러스 제조물
|
MXPA03003690A
(es)
|
2000-10-27 |
2004-05-05 |
Chiron Spa |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
WO2002046477A2
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
WO2002080648A2
(en)
*
|
2001-04-05 |
2002-10-17 |
Chiron Corporation |
Mucosal boosting following parenteral priming
|
JP2005504513A
(ja)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
前立腺癌の治療及び診断のための組成物及び方法
|
MY134424A
(en)
*
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
WO2003002065A2
(en)
|
2001-06-29 |
2003-01-09 |
Chiron Corporation |
Hcv e1e2 vaccine compositions
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
AU2002365279B2
(en)
|
2001-12-17 |
2009-08-13 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
US8088388B2
(en)
|
2002-02-14 |
2012-01-03 |
United Biomedical, Inc. |
Stabilized synthetic immunogen delivery system
|
EP2572707A3
(en)
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
SE0201701D0
(sv)
*
|
2002-06-05 |
2002-06-05 |
Gotovax Ab |
Treatment of epithelial tumors and infections
|
EP1532161B1
(en)
|
2002-06-13 |
2012-02-15 |
Novartis Vaccines and Diagnostics, Inc. |
Vectors for expression of hml-2 polypeptides
|
EP1387167B1
(en)
*
|
2002-07-24 |
2008-05-07 |
Centre National De La Recherche Scientifique (Cnrs) |
Method for identifying biologically active compounds with anti-asthmatic and/or anti-allergic properties
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
US20040132652A1
(en)
*
|
2002-08-30 |
2004-07-08 |
Shire Biochem Inc. |
Pharmaceutical compositions
|
ES2608048T3
(es)
|
2002-10-11 |
2017-04-05 |
Glaxosmithkline Biologicals Sa |
Vacunas polipeptídicas para protección amplia contra linajes meningocócicos hipervirulentos
|
PT2241325E
(pt)
|
2002-10-29 |
2012-04-12 |
Coley Pharm Gmbh |
Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
MXPA05007295A
(es)
|
2003-01-06 |
2005-09-30 |
Corixa Corp |
Ciertos compuestos de fosfato de aminoalquil glucosaminida y su uso.
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
CA2514328C
(en)
|
2003-01-30 |
2020-01-14 |
Chiron Srl |
Injectable vaccines against multiple meningococcal serogroups
|
EP2258365B1
(en)
|
2003-03-28 |
2013-05-29 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US20060257852A1
(en)
|
2003-04-10 |
2006-11-16 |
Chiron Corporation |
Severe acute respiratory syndrome coronavirus
|
WO2005020964A1
(en)
|
2003-06-02 |
2005-03-10 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
DK1961426T3
(da)
|
2003-10-02 |
2011-08-08 |
Novartis Ag |
Kombinationsvacciner mod meningitis
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
CA2551560A1
(en)
|
2003-12-23 |
2005-07-14 |
Arbor Vita Corporation |
Antibodies for oncogenic strains of hpv and methods of their use
|
DE202005022108U1
(de)
|
2004-03-09 |
2013-11-12 |
Novartis Vaccines And Diagnostics, Inc. |
Influenza-Virus-Impfstoffe
|
RU2379052C2
(ru)
|
2004-04-30 |
2010-01-20 |
Чирон С.Р.Л. |
Вакцинация менингококковыми конъюгатами
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP2811027A1
(en)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for RSV and PIV vaccines
|
EP1766096B1
(en)
|
2004-05-25 |
2013-01-02 |
Oregon Health and Science University |
Hiv vaccination usingand hcmv-based vaccine vectors
|
JP2008504292A
(ja)
|
2004-06-24 |
2008-02-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
免疫増強用の化合物
|
EP1768662A2
(en)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
EP1784211A4
(en)
|
2004-07-29 |
2010-06-30 |
Novartis Vaccines & Diagnostic |
IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
CN101107007B
(zh)
|
2005-01-27 |
2011-08-17 |
奥克兰儿童医院及研究中心 |
对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
SG160329A1
(en)
|
2005-02-18 |
2010-04-29 |
Novartis Vaccines & Diagnostic |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
CN101203529A
(zh)
|
2005-02-18 |
2008-06-18 |
诺华疫苗和诊断公司 |
来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
|
CN101184504A
(zh)
|
2005-03-31 |
2008-05-21 |
葛兰素史密丝克莱恩生物有限公司 |
针对衣原体感染的疫苗
|
CN101237881B
(zh)
*
|
2005-08-03 |
2015-04-22 |
伊缪诺金公司 |
免疫偶联物剂型
|
JP2009511636A
(ja)
|
2005-10-18 |
2009-03-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
|
EP1776963A1
(en)
|
2005-10-19 |
2007-04-25 |
Gbf-Gesellschaft Für Biotechnologische Forschung Mbh |
Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
|
ES2420829T3
(es)
|
2005-11-04 |
2013-08-27 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
|
JP5215865B2
(ja)
|
2005-11-22 |
2013-06-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
ノロウイルス抗原およびサポウイルス抗原
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
EA015271B1
(ru)
|
2006-01-27 |
2011-06-30 |
Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг |
Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
EP2004226A1
(en)
|
2006-03-24 |
2008-12-24 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Storage of influenza vaccines without refrigeration
|
US20100285062A1
(en)
|
2006-03-31 |
2010-11-11 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
EP2054431B1
(en)
|
2006-06-09 |
2011-08-31 |
Novartis AG |
Conformers of bacterial adhesins
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
EP2064230A2
(en)
|
2006-08-16 |
2009-06-03 |
Novartis AG |
Immunogens from uropathogenic escherichia coli
|
EP1897557A1
(en)
*
|
2006-09-07 |
2008-03-12 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Use of glycolipids as adjuvants
|
KR20090057015A
(ko)
|
2006-09-11 |
2009-06-03 |
노파르티스 아게 |
난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
|
US20110045022A1
(en)
|
2006-12-06 |
2011-02-24 |
Theodore Tsai |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
WO2008124647A2
(en)
|
2007-04-04 |
2008-10-16 |
Infectious Disease Research Institute |
Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
|
PL2185191T3
(pl)
|
2007-06-27 |
2013-02-28 |
Novartis Ag |
Szczepionki przeciwko grypie o małej zawartości dodatków
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
US8747861B2
(en)
|
2007-08-02 |
2014-06-10 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope influenza vaccines
|
CN102027003A
(zh)
|
2007-08-03 |
2011-04-20 |
哈佛大学校长及研究员协会 |
衣原体抗原
|
RU2471497C2
(ru)
|
2007-09-12 |
2013-01-10 |
Новартис Аг |
Мутантные антигены gas57 и антитела против gas57
|
EP2570137A3
(en)
|
2007-11-07 |
2013-08-21 |
Celldex Therapeutics, Inc. |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
EP2227250A4
(en)
|
2007-12-03 |
2011-07-06 |
Harvard College |
ANTIGENS OF CHLAMYDIA
|
EP2244695A1
(en)
|
2007-12-07 |
2010-11-03 |
Novartis AG |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
WO2009081274A2
(en)
|
2007-12-21 |
2009-07-02 |
Novartis Ag |
Mutant forms of streptolysin o
|
CA2716212A1
(en)
|
2008-02-21 |
2009-08-27 |
Novartis Ag |
Meningococcal fhbp polypeptides
|
EP2265640B1
(en)
|
2008-03-10 |
2015-11-04 |
Children's Hospital & Research Center at Oakland |
Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
|
AU2009323682A1
(en)
|
2008-12-03 |
2010-06-10 |
Protea Vaccine Technologies Ltd. |
Glutamyl tRNA synthetase (GtS) fragments
|
PE20110891A1
(es)
|
2008-12-09 |
2011-12-23 |
Pfizer Vaccines Llc |
Vacuna de peptido ch3 de ige
|
CA2749367A1
(en)
|
2009-01-12 |
2010-07-15 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
EP3263128A3
(en)
|
2009-04-14 |
2018-01-24 |
GlaxoSmithKline Biologicals S.A. |
Compositions for immunising against staphylococcus aureus
|
KR101450958B1
(ko)
|
2009-04-30 |
2014-10-15 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
폐렴구균 백신 및 그의 용도
|
EP2442826B1
(en)
|
2009-06-15 |
2015-07-08 |
National University of Singapore |
Influenza vaccine, composition, and methods of use
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
WO2011008974A2
(en)
|
2009-07-15 |
2011-01-20 |
Novartis Ag |
Rsv f protein compositions and methods for making same
|
MX2012000734A
(es)
|
2009-07-16 |
2012-01-27 |
Novartis Ag |
Inmunogenos destoxificados de escherichia coli.
|
CN102596236B
(zh)
|
2009-07-30 |
2015-06-24 |
辉瑞疫苗有限责任公司 |
抗原性Tau肽及其用途
|
CA2772104A1
(en)
|
2009-08-27 |
2011-03-03 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
AU2010290931B2
(en)
|
2009-09-03 |
2014-02-06 |
Pfizer Vaccines Llc |
PCSK9 vaccine
|
AU2010352695B2
(en)
|
2009-09-30 |
2014-08-21 |
Glaxosmithkline Biologicals S.A. |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
CA2779816A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
EP2496609A4
(en)
|
2009-11-03 |
2013-05-08 |
Ligocyte Pharmaceuticals Inc |
CHIMERIC RSV-F POLYPEPTIDE AND VLPS ON LENTIVIREN OR ALPHA RETROVIRUS GAG BASE
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
MX337070B
(es)
|
2009-12-22 |
2016-02-11 |
Celldex Therapeutics Inc |
Método para preparar un conjugado klh-egfrviii.
|
WO2011080595A2
(en)
|
2009-12-30 |
2011-07-07 |
Novartis Ag |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
ES2910199T3
(es)
|
2010-03-30 |
2022-05-11 |
Childrens Hospital & Res Center At Oakland |
Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011127316A1
(en)
|
2010-04-07 |
2011-10-13 |
Novartis Ag |
Method for generating a parvovirus b19 virus-like particle
|
NZ623807A
(en)
|
2010-04-13 |
2016-03-31 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
WO2011130379A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Benzonapthyridine compositions and uses thereof
|
CN102933267B
(zh)
|
2010-05-28 |
2015-05-27 |
泰特里斯在线公司 |
交互式混合异步计算机游戏基础结构
|
CA2798837A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
EP2942061A3
(en)
|
2010-06-07 |
2016-01-13 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
EP3153578A1
(en)
|
2010-07-06 |
2017-04-12 |
Novartis Ag |
Norovirus derived immunogenic compositions and methods
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US20130345079A1
(en)
|
2010-10-27 |
2013-12-26 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
WO2012064659A1
(en)
|
2010-11-08 |
2012-05-18 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
BR112013014598A2
(pt)
*
|
2010-12-14 |
2017-09-19 |
Glaxosmithkline Biologicals Sa |
composição imunogênica, uso de uma composição imunogênica, processo para preparar uma composição imunogênica, método para a fabricação de uma composição imunogênica estável, e, kit
|
EP2655389A2
(en)
|
2010-12-24 |
2013-10-30 |
Novartis AG |
Compounds
|
HUE043879T2
(hu)
|
2011-01-26 |
2019-09-30 |
Glaxosmithkline Biologicals Sa |
RSV-immunizálási rend
|
CN103517713A
(zh)
|
2011-02-22 |
2014-01-15 |
彼昂德瓦克斯医药有限公司 |
在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
DK3275892T3
(da)
|
2011-05-13 |
2020-04-06 |
Glaxosmithkline Biologicals Sa |
Præfusions-rsv-f-antigener
|
MX2013013627A
(es)
|
2011-06-21 |
2014-04-25 |
Oncofactor Corp |
Composiciones y metodos para la terapia y diagnostico de cancer.
|
US11058762B2
(en)
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
EP2736921B1
(en)
|
2011-07-25 |
2018-06-27 |
GlaxoSmithKline Biologicals SA |
Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2755994A2
(en)
|
2011-09-14 |
2014-07-23 |
Novartis AG |
Escherichia coli vaccine combination
|
SG11201402375VA
(en)
|
2011-12-08 |
2014-10-30 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
RU2014138418A
(ru)
|
2012-02-24 |
2016-04-10 |
Новартис Аг |
Белки пилей и композиции
|
EP3492095A1
(en)
|
2012-04-01 |
2019-06-05 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
AU2013254751B2
(en)
|
2012-04-26 |
2017-12-14 |
Glaxosmithkline Biologicals S.A. |
Antigens and antigen combinations
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
PE20142406A1
(es)
|
2012-05-04 |
2015-01-23 |
Pfizer |
Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
|
MX2014014067A
(es)
|
2012-05-22 |
2015-02-04 |
Novartis Ag |
Conjugado de serogrupo x de meningococo.
|
WO2014005958A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
HRP20240164T1
(hr)
|
2012-08-03 |
2024-04-12 |
Access To Advanced Health Institute |
Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama
|
CN105307684A
(zh)
|
2012-10-02 |
2016-02-03 |
葛兰素史密丝克莱恩生物有限公司 |
非直链糖缀合物
|
JP6266000B2
(ja)
|
2012-10-03 |
2018-01-24 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
RS56886B1
(sr)
|
2012-11-30 |
2018-04-30 |
Glaxosmithkline Biologicals Sa |
Antigeni pseudomonasa i kombinacije antigena
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
WO2015132619A1
(en)
|
2013-05-15 |
2015-09-11 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP3096785B1
(en)
|
2014-01-21 |
2020-09-09 |
Pfizer Inc |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US10279019B2
(en)
|
2014-02-11 |
2019-05-07 |
Stc.Unm |
PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
|
EP4074726A3
(en)
|
2014-07-23 |
2022-11-23 |
Children's Hospital & Research Center at Oakland |
Factor h binding protein variants and methods of use thereof
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
WO2016097865A1
(en)
|
2014-12-19 |
2016-06-23 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
HRP20230416T1
(hr)
|
2015-01-15 |
2023-07-07 |
Pfizer Inc. |
Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
RU2017140856A
(ru)
|
2015-05-26 |
2019-06-26 |
Огайо Стейт Инновейшн Фаундейшн |
Стратегия вакцинации против вируса свиного гриппа вакциной на основе наночастиц
|
CA2986494A1
(en)
|
2015-06-03 |
2016-12-08 |
Affiris Ag |
Il-23-p19 vaccines
|
EP3319988A1
(en)
|
2015-07-07 |
2018-05-16 |
Affiris AG |
Vaccines for the treatment and prevention of ige mediated diseases
|
CN108367063A
(zh)
|
2015-07-21 |
2018-08-03 |
辉瑞公司 |
包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
|
JP6884145B2
(ja)
|
2015-11-20 |
2021-06-09 |
ファイザー・インク |
肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
|
CA2954892A1
(en)
|
2016-01-19 |
2017-07-19 |
Pfizer Inc. |
Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトcd40に結合するアゴニスト抗体およびその使用
|
CN109310748A
(zh)
|
2016-05-21 |
2019-02-05 |
传染病研究所 |
用于治疗继发性结核和非结核分枝杆菌感染的组合物和方法
|
US11801290B2
(en)
|
2016-09-16 |
2023-10-31 |
Access To Advanced Health Institute |
Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
MX2019008564A
(es)
|
2017-01-20 |
2019-09-19 |
Pfizer |
Composiciones inmunogenicas para su uso en vacunas neumococicas.
|
US11123415B2
(en)
|
2017-08-16 |
2021-09-21 |
Ohio State Innovation Foundation |
Nanoparticle compositions for Salmonella vaccines
|
BR112020008652A2
(pt)
|
2017-11-03 |
2020-11-10 |
Takeda Vaccines, Inc. |
vacinas e composições imunogênicas contra zika e métodos de uso das mesmas
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
AU2019256383A1
(en)
|
2018-04-17 |
2020-11-26 |
Celldex Therapeutics, Inc. |
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP7320601B2
(ja)
|
2018-09-11 |
2023-08-03 |
上▲海▼市公共▲衛▼生▲臨▼床中心 |
広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
|
WO2020123444A1
(en)
|
2018-12-11 |
2020-06-18 |
Celldex Therapeutics, Inc. |
Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
|
WO2020121159A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
EP3952906A1
(en)
|
2019-04-10 |
2022-02-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
EP4051696A1
(en)
|
2019-11-01 |
2022-09-07 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
AU2021211012A1
(en)
|
2020-01-24 |
2022-08-25 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
JP2021132644A
(ja)
|
2020-02-21 |
2021-09-13 |
ファイザー・インク |
糖の精製
|
JP2023514697A
(ja)
|
2020-02-23 |
2023-04-07 |
ファイザー・インク |
大腸菌組成物およびその方法
|
US20240148858A1
(en)
*
|
2020-07-24 |
2024-05-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
A three component vaccine for covid-19
|
KR20230096033A
(ko)
|
2020-10-27 |
2023-06-29 |
화이자 인코포레이티드 |
에스케리키아 콜라이 조성물 및 그의 방법
|
US20240000912A1
(en)
|
2020-11-04 |
2024-01-04 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
US20230405137A1
(en)
|
2020-11-10 |
2023-12-21 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
US20220265805A1
(en)
|
2021-02-19 |
2022-08-25 |
Sanofi Pasteur Inc. |
Meningococcal b recombinant vaccine
|
IL307519A
(en)
|
2021-04-09 |
2023-12-01 |
Celldex Therapeutics Inc |
Antibodies against ILT4, anti-ILT4\PD-L1 bispecific antibody and their uses
|
EP4333868A1
(en)
|
2021-05-04 |
2024-03-13 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
TW202304503A
(zh)
|
2021-05-28 |
2023-02-01 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
CA3221075A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
WO2023092090A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
KR102420201B1
(ko)
*
|
2022-01-17 |
2022-07-13 |
주식회사 유이케미칼 |
인지질 외피 보유 바이러스 사멸기능을 가지는 친환경 방역 조성물
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024018061A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
|